NextCure discontinues NC762, prioritizes LNCB74 ADC; NC410 data expected H1 2024

NextCure, Inc.

NC410 (LAIR-2 fusion) combination with pembrolizumab adding patients to 100 mg cohort for microsatellite stable colorectal cancer without liver mets; data expected H1 2024.
NC762 (B7-H4 mAb) development halted due to competitive environment and limited activity; resources shifted to LNCB74 (B7-H4 ADC).
LNCB74 set to initiate dose range-finding toxicology study and GMP manufacturing in early 2024.
NC525 (LAIR-1 mAb) Phase 1a dose escalation ongoing (4th cohort enrolled); safe and well tolerated; data expected H1 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.